Swiss Dental Startup vVARDIS Lists on NYSE Under Ticker VVVV
vVARDIS debuts on the New York Stock Exchange with a drill-free cavity treatment targeting the world's most common non-communicable disease.
Swiss dental health company vVARDIS began trading on the New York Stock Exchange on Nov. 13, 2026, under the ticker symbol VVVV, marking a significant milestone for a startup that has built its business around a non-invasive approach to treating tooth decay.
Co-founders Dr. Haley Abivardi and Dr. Goly Abivardi have positioned vVARDIS around a core premise: cavities, widely classified as the world's most prevalent non-communicable disease, have long been treated with drilling and filling — a model the company argues is overdue for disruption. Their technology offers a drill-free alternative aimed at the hundreds of millions of patients who develop cavities each year.
Read more Inverse Anthropic ETFs ANDD and ANSS Offer Bearish Bets on ANT →
The NYSE listing represents a vote of confidence from public markets in the company's commercial ambitions. By going public, vVARDIS gains access to capital that could accelerate distribution of its treatment technology across dental practices, potentially reshaping standard-of-care protocols that have remained largely unchanged for decades.
The dental health sector has attracted growing investor interest as preventive and minimally invasive treatments gain traction with both patients and practitioners. vVARDIS enters the public markets as a rare pure-play bet on next-generation cavity care, with its founders' scientific credentials and the scale of the addressable patient population serving as central parts of its investment thesis.
Continue reading at All Financial Services & Investing.